Sònia Pernas

5.5k total citations · 1 hit paper
109 papers, 1.6k citations indexed

About

Sònia Pernas is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Sònia Pernas has authored 109 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 89 papers in Oncology, 57 papers in Pulmonary and Respiratory Medicine and 45 papers in Cancer Research. Recurrent topics in Sònia Pernas's work include HER2/EGFR in Cancer Research (49 papers), Advanced Breast Cancer Therapies (49 papers) and Cancer Treatment and Pharmacology (39 papers). Sònia Pernas is often cited by papers focused on HER2/EGFR in Cancer Research (49 papers), Advanced Breast Cancer Therapies (49 papers) and Cancer Treatment and Pharmacology (39 papers). Sònia Pernas collaborates with scholars based in Spain, United States and Italy. Sònia Pernas's co-authors include Sara M. Tolaney, Shom Goel, Eric P. Winer, Aleix Prat, Noelia Martínez-Jáñez, Romualdo Barroso‐Sousa, Begoña Bermejo, Serafín Morales, Antonio Llombart‐Cussac and Javier Cortés and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Sònia Pernas

100 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance

2019 256 citations Sònia Pernas, Sara M. Tolaney profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sònia Pernas Spain	20	1.1k	545	447	413	312	109	1.6k
Zhimin Shao China	22	1.1k 1.0×	557 1.0×	557 1.2×	516 1.2×	290 0.9×	90	1.8k
Ying Fan China	23	1.1k 1.0×	697 1.3×	513 1.1×	542 1.3×	194 0.6×	120	1.7k
Akihiko Shimomura Japan	22	1.1k 1.0×	537 1.0×	536 1.2×	751 1.8×	331 1.1×	132	2.0k
Zhongsheng Tong China	20	1.2k 1.1×	372 0.7×	754 1.7×	324 0.8×	264 0.8×	105	1.7k
Emanuela Ferraro United States	14	923 0.8×	434 0.8×	399 0.9×	335 0.8×	349 1.1×	54	1.3k
Noam Pondé Belgium	19	981 0.9×	488 0.9×	372 0.8×	324 0.8×	212 0.7×	52	1.4k
Serafín Morales Spain	16	1.2k 1.0×	494 0.9×	574 1.3×	362 0.9×	345 1.1×	134	1.6k
Cesar A. Santa‐Maria United States	19	1.1k 1.0×	646 1.2×	449 1.0×	692 1.7×	235 0.8×	67	1.9k
Qingyuan Zhang China	22	1.3k 1.2×	331 0.6×	617 1.4×	376 0.9×	291 0.9×	76	1.9k
Conleth G. Murphy Ireland	19	1.0k 0.9×	218 0.4×	430 1.0×	322 0.8×	188 0.6×	55	1.5k

Countries citing papers authored by Sònia Pernas

Since Specialization

Citations

This map shows the geographic impact of Sònia Pernas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sònia Pernas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sònia Pernas more than expected).

Fields of papers citing papers by Sònia Pernas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sònia Pernas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sònia Pernas. The network helps show where Sònia Pernas may publish in the future.

Co-authorship network of co-authors of Sònia Pernas

This figure shows the co-authorship network connecting the top 25 collaborators of Sònia Pernas. A scholar is included among the top collaborators of Sònia Pernas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sònia Pernas. Sònia Pernas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

García‐Tejedor, Amparo, Agostina Stradella, Hector Pérez, et al.. (2025). Prognostic Outcomes by Axillary Approach in Lobular and Ductal Breast Cancer With Sentinel Node Macrometastases: A Retrospective Cohort Study. Clinical Breast Cancer. 26(1). 262–275.

Ignatiadis, Michail, Emmanouil Saloustros, Ciara M. Kelly, et al.. (2024). 338TiP EORTC-2129-BCG: Elacestrant for treating ER+/HER2- breast cancer patients with ctDNA relapse (TREAT ctDNA). Annals of Oncology. 35. S355–S356. 2 indexed citations

Lorenzo-Esteller, Laia, Javier Berdejo, Sònia Pernas, et al.. (2024). Pericardial Disease in Patients with Cancer: Clinical Insights on Diagnosis and Treatment. Cancers. 16(20). 3466–3466. 8 indexed citations

Martínez-Jáñez, Noelia, Sònia Pernas, José Á. García-Sáenz, et al.. (2024). Abstract PO4-05-09: Phase I study of the FGFR inhibitor rogaratinib, fulvestrant and palbociclib in advanced hormone receptor-positive (HR+) breast cancer (BC) with FGFR1/2 amplification and/or overexpression (FGFR1/2+). Cancer Research. 84(9_Supplement). PO4–5. 2 indexed citations

Pernas, Sònia, Seock‐Ah Im, Masaya Hattori, et al.. (2024). Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Patient-reported outcomes (PROs) from the TROPION-Breast01 study.. Journal of Clinical Oncology. 42(16_suppl). 1006–1006. 1 indexed citations

Ciruelos, Eva, Tomás Pascual, Guillermo Villacampa, et al.. (2024). Primary results from PATRICIA cohort C (SOLTI-1303), a randomized phase II study evaluating palbociclib with trastuzumab and endocrine therapy in pretreated HER2-positive and PAM50 luminal advanced breast cancer.. Journal of Clinical Oncology. 42(16_suppl). 1008–1008. 4 indexed citations

Pernas, Sònia, Esther Sanfeliu, Guillermo Villacampa, et al.. (2024). Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy. npj Breast Cancer. 10(1). 101–101.

Pernas, Sònia, Raül Rigo‐Bonnin, Àlex Teulé, et al.. (2024). Everolimus Through Plasmatic Concentrations in Cancer Patients: Prospective Longitudinal Observational Multicentric Study (DIANA-1 Project). Journal of Clinical Medicine. 14(1). 145–145. 1 indexed citations

Im, Seock‐Ah, Shoei‐Shen Wang, Yen‐Shen Lu, et al.. (2024). PS3-1 Dato-DXd vs. chemotherapy for patients with inoperable/metastatic HR+/HER2− breast cancer: TROPION-Breast01 Asian subset. Annals of Oncology. 35. S1314–S1314.

10.

Pascual, Tomás, Juan Miguel Cejalvo, Mafalda Oliveira, et al.. (2023). 387MO First results of the SOLTI-1903 HOPE's patient-centric molecular screening program in advanced breast cancer. Annals of Oncology. 34. S341–S342. 1 indexed citations

11.

Pernas, Sònia, Audrey Petit, Ander Urruticoechea, et al.. (2021). 14P Immunomodulatory effect of denosumab in early breast cancer: Preliminary results of a randomized window-opportunity clinical trial D-Biomark. Annals of Oncology. 32. S26–S26. 1 indexed citations

12.

Griguolo, Gaia, Garazi Serna, Tomás Pascual, et al.. (2020). 8P Characterization of immune microenvironment before and following anti-HER2 neoadjuvant therapy (NAT). Annals of Oncology. 31. S19–S19. 1 indexed citations

13.

Ocaña, Alberto, Marta Gil-Martín, Silvia Antolín, et al.. (2019). Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 study. Breast Cancer Research and Treatment. 174(3). 693–701. 36 indexed citations

14.

Ayala, Francisco, Raquel Andrés, José Á. García-Sáenz, et al.. (2018). SEOM clinical guidelines in early stage breast cancer (2018). Clinical & Translational Oncology. 21(1). 18–30. 47 indexed citations

15.

Pernas, Sònia, Romualdo Barroso‐Sousa, & Sara M. Tolaney. (2018). Optimal treatment of early stage HER2‐positive breast cancer. Cancer. 124(23). 4455–4466. 50 indexed citations

16.

Borrego, Manuel Ruíz, Marta Gil-Martín, Silvia Antolín, et al.. (2017). A phase II trial of dasatinib (D) in combination with trastuzumab (T) and paclitaxel (P) in the first line treatment of HER2 positive metastatic breast cancer (MBC) patients (pts): GEICAM/2010-04. Annals of Oncology. 28. v75–v75. 1 indexed citations

17.

García‐Tejedor, Amparo, Catalina Falo, Teresa Soler, et al.. (2017). Feasibility, accuracy and prognosis of sentinel lymph node biopsy before neoadjuvant therapy in breast cancer. A prospective study. International Journal of Surgery. 39. 141–147. 7 indexed citations

18.

Martı́n-Castillo, Begoña, Eugeni López‐Bonet, Elisabet Cuyàs, et al.. (2015). Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas. Oncotarget. 6(32). 32317–32338. 29 indexed citations

19.

Domenech, Arnau, et al.. (2009). What are the preoperative factors that can determine the presence of metastases in other axillary nodes in breast cancer when the sentinel node is positive?. PubMed. 53(4). 422–7. 4 indexed citations

20.

Pernas, Sònia, Marta Gil, Fina Climent, et al.. (2009). Avoiding Axillary Treatment in Sentinel Lymph Node Micrometastases of Breast Cancer: A Prospective Analysis of Axillary or Distant Recurrence. Annals of Surgical Oncology. 17(3). 772–777. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact